Drug Type Small molecule drug |
Synonyms Galida, Tesaglitazar (JAN/USAN/INN), AR-H-039242 + [8] |
Target |
Action agonists |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H24O7S |
InChIKeyCXGTZJYQWSUFET-IBGZPJMESA-N |
CAS Registry251565-85-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01274 | Tesaglitazar | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Familial HDL Deficiency | Phase 3 | Brazil | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Canada | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Finland | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | France | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Germany | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Hong Kong | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Hungary | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | India | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Indonesia | 01 Mar 2005 | |
| Familial HDL Deficiency | Phase 3 | Malaysia | 01 Mar 2005 |
Phase 2 | - | nrbcbelcvh(rysgnoxizz) = nqcyfclcyq tcovlyvfsu (kigssvxtay ) | - | 01 Dec 2006 | |||
nrbcbelcvh(rysgnoxizz) = niywbmhkqb tcovlyvfsu (kigssvxtay ) |





